RPIDHIGH SIGNALFINANCIAL10-K

RPID shows concerning financial deterioration with total liabilities surging 82.5% and stockholders' equity plummeting 55.9% despite revenue growth, indicating potential liquidity or capital structure stress.

The massive increase in liabilities combined with the dramatic decline in equity suggests significant financial stress or restructuring that wasn't adequately explained in the operational updates. While revenue growth of 19.7% appears positive, it's overshadowed by the balance sheet deterioration and continued substantial operating cash flow losses.

Comparing 2026-03-12 vs 2025-02-28View on EDGAR →
FINANCIAL ANALYSIS

RPID presents a mixed but concerning financial picture where revenue grew 19.7% to $33.6M and operating cash flow losses improved 29.6%, yet the balance sheet shows severe deterioration with liabilities jumping 82.5% and stockholders' equity collapsing 55.9%. Total assets declined 23.8% while accounts receivable fell dramatically by 58.3%, suggesting potential collection issues or changes in business terms. The overall picture signals significant financial stress despite operational improvements, with the liability surge and equity decline representing major red flags for investors about the company's capital structure and financial stability.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
+82.5%
$22.8M$41.6M

Liabilities grew 82.5% — significant increase in debt or obligations, assess impact on financial flexibility.

Accounts Receivable
Balance Sheet
-58.3%
$7.5M$3.1M

Receivables declined — improved collection efficiency or conservative revenue recognition.

Stockholders Equity
Balance Sheet
-55.9%
$75.4M$33.2M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Capital Expenditure
Cash Flow
-37.7%
$1.4M$850K

Capex reduced 37.7% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Cash Flow
Cash Flow
+29.6%
-$44.2M-$31.1M

Operating cash flow grew 29.6% — strong conversion of earnings to cash, healthy business fundamentals.

Current Assets
Balance Sheet
-24.4%
$80.9M$61.2M

Current assets declined 24.4% — monitor working capital adequacy and short-term liquidity.

Total Assets
Balance Sheet
-23.8%
$98.2M$74.9M

Total assets contracted 23.8% — asset sales, write-downs, or balance sheet optimization underway.

Interest Expense
P&L
-23.1%
$3.4M$2.6M

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Revenue
P&L
+19.7%
$28.1M$33.6M

Revenue growing 19.7% — solid top-line momentum, watch margins for quality of growth.

Cash & Equivalents
Balance Sheet
+18.4%
$16.9M$20.0M

Cash grew 18.4% — improving liquidity position supports investment and shareholder returns.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-02-28
ADDED
These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.
You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed as exhibits to this Annual Report on Form 10-K with the understanding that our actual future results, levels of activity, performance and achievements may be materially different from what we expect.
Our platform comprises the Growth Direct system, proprietary consumables, lab information management system ("LIMS") connection and other software, and comprehensive customer support and validation services.
We have placed 190 systems and sold approximately 9 million consumables globally.
Our customer base includes 75% of the top twenty largest pharmaceutical companies as measured by revenue and the manufacturers of a number of U.S.
+7 more — sign up free →
REMOVED
Our platform comprises the Growth Direct system, proprietary consumables, lab information management system, or LIMS, connection software, and comprehensive customer support and validation services.
We launched our current, second generation Growth Direct system in 2017 and have placed 162 systems and sold over 6 million consumables globally.
Our customer base includes 70% of the top twenty largest pharmaceutical companies as measured by revenue and the manufacturers of approximately 17% of U.S.
Rebuilding of domestic growth supply chain / increasing scrutiny of outsourced materials with focus on reshoring drug development process We believe the reshoring of manufacturing operations will further necessitate the need for efficient automated MQC testing.
The Growth Direct system Our current, second-generation Growth Direct system, launched in 2017, reflects our deep experience with delivering automation to the MQC market.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →